A Phase 2 interventional study of Biospecimen Collection and Bone Marrow Aspirate in Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, sponsored by Fred Hutchinson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 6 Months to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Fred Hutchinson Cancer Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing cyclophosphamide in Leukemia, Biphenotypic, Acute — 6 open to participants now, 8 under way, none of them phase 3. Cyclophosphamide · Leukemia, Biphenotypic, Acute.
Among the 23 studies testing cyclophosphamide in Leukemia, Biphenotypic, Acute, this one is the 11th largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2024, is one of 16 in phase 2, and was the 22nd registered.
246 studies on the registry are indexed under Leukemia, Biphenotypic, Acute; 53 are open to participants now.
Browse Leukemia, Biphenotypic, Acute studies →6 of the 23 studies testing cyclophosphamide in Leukemia, Biphenotypic, Acute are open now, in 2 countries. Recruiting first, the newest first:
Sheng-Li Xue, MD · Sites in China
Ages 15+
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages up to 75
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 14+
M.D. Anderson Cancer Center · Sites in United States
Ages 15–80
Fred Hutchinson Cancer Center · Sites in United States
By country, each count listing its studies:
Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →
Of the 47 Leukemia, Biphenotypic, Acute studies recruiting now, 21 (45%) set no upper age limit and 21 (45%) stop at 75 or younger; 29 take children under 18; 3 take healthy volunteers.
This study: 6 Months to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 1
First in 1996; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 54 is close to the median of 50 across 185 interventional studies indexed under Leukemia, Biphenotypic, Acute.
Median enrollment 54 across the 21 interventional studies. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 23 has an industry lead sponsor. The 10 most frequent:
Fred Hutchinson Cancer Center is the lead sponsor of 547 studies on the registry; 79 are open to participants now.
Of its 59 completed or terminated interventional studies of FDA-regulated products, 46 (78%) have results posted.
32 studies in Leukemia, Biphenotypic, Acute by Fred Hutchinson Cancer Center: 9 open now, 12 under way, none of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 32 studies in Leukemia, Biphenotypic, Acute by Fred Hutchinson Cancer Center, this one is the 11th largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2024, is one of 17 in phase 2, reaches primary completion later than 11 of the 11 other live ones, and was the 28th registered.
Fred Hutchinson Cancer Center’s Leukemia, Biphenotypic, Acute studies by the year they started, since 1996.
3 of the studies testing cyclophosphamide in Leukemia, Biphenotypic, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06001385Center for International Blood and Marrow Transplant ResearchHLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | 2026-12-24 |
| NCT02727803M.D. Anderson Cancer CenterPersonalized NK Cell Therapy in CBT | 2027-05-31 |
| NCT05805605Masonic Cancer Center, University of MinnesotaAllo HSCT Using RIC and PTCy for Hematological Diseases | 2027-10-22 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing cyclophosphamide in Leukemia, Biphenotypic, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Fred Hutchinson Cancer Center’s 32 in Leukemia, Biphenotypic, Acute:
This tab as a report to print or save as PDF → With an account.
This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosphamide, fludarabine and thiotepa, and TBI before a donor cord blood transplant (CBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening in patients with high-risk hematologic diseases.
OUTLINE: Patients are assigned to 1 of 2 arms.
ARM I: Patients aged 6 months through 30 years old receive myeloablative conditioning comprising fludarabine intravenously (IV) over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 and -6, and undergo high-dose TBI twice daily (BID) on days -4 to -1. Patients then undergo UCBT on day 0. Patients undergo blood sample collection throughout the study. Patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) and diagnostic imaging during screening and as clinically indicated on study. Patients also undergo blood sample collection throughout the study and bone marrow aspirate during screening and on study.
ARM II: Patients aged 6 months through 65 years old receive myeloablative conditioning comprising fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 2-4 hours on days -5 and -4, and middle-intensity TBI once daily (QD) on days -2 and -1. Patients then undergo UCBT on day 0. Patients undergo ECHO or MUGA and diagnostic imaging during screening and as clinically indicated on study. Patients also undergo blood sample collection throughout the study and bone marrow aspirate during screening and on study.
All patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine orally (PO) (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 14 and then PO (if tolerated) three times daily (TID) on days 15-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred > day 30) after engraftment if there continues to be no evidence of acute GVHD.
After completion of study treatment, patients are followed up at day 180, 1 year, and 2 years.
The criteria were revised on the registry on Oct 26, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Acute myelogenous leukemia (AML):
Acute lymphoblastic leukemia (ALL):
Complete first remission (CR1) at high risk for relapse such as any of the following:
Complete second remission (CR2) or greater (CR2+).
Myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD) other than myelofibrosis:
Non-Hodgkin lymphoma (NHL) at high-risk of relapse or progression if not in remission:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
See detailed description.
Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspirate · Drug: Cyclophosphamide · Drug: Cyclosporine · Procedure: Diagnostic Imaging Testing · Procedure: Echocardiography Test · Drug: Fludarabine Phosphate · Procedure: Multigated Acquisition Scan · Drug: Mycophenolate Mofetil · Other: Survey Administration · Radiation: Total-Body Irradiation · Procedure: Umbilical Cord Blood Transplantation
See detailed description.
Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspirate · Drug: Cyclophosphamide · Drug: Cyclosporine · Procedure: Diagnostic Imaging Testing · Procedure: Echocardiography Test · Drug: Fludarabine Phosphate · Procedure: Multigated Acquisition Scan · Drug: Mycophenolate Mofetil · Other: Survey Administration · Drug: Thiotepa · Radiation: Total-Body Irradiation · Procedure: Umbilical Cord Blood Transplantation
Undergo blood sample collection
Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection
Undergo bone marrow aspirate
Also known as: BONE MARROW, LIQUID, Human Bone Marrow Aspirate
Given IV
Also known as: (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Asta B 518, B-518, WR-138719, Frindovyx
Given IV or PO
Also known as: 27-400, Ciclosporin, CsA, Cyclosporin, Cyclosporin A, Cyclosporine Modified, Gengraf, Neoral, OL 27-400, Sandimmune, SangCya
Undergo diagnostic imaging
Also known as: Diagnostic Imaging, Medical Imaging
Undergo ECHO
Also known as: EC, Echocardiography
Given IV
Also known as: 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586
Undergo MUGA
Also known as: Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning
Given IV
Also known as: CellCept, MMF
Ancillary studies
Given IV
Also known as: 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, SH105
Undergo high-dose or middle-intensity TBI
Also known as: SCT_TBI, TBI, Total Body Irradiation, Whole Body, Whole Body Irradiation, Whole-Body Irradiation
Undergo UCBT
Also known as: Cord Blood, Cord Blood Transplantation, UCB transplantation, UMBILICAL CORD BLOOD TRANSPLANT
Overall survival
Will be assessed after optimized cord blood transplant (CBT) in adults and children with hematologic malignancies. Will be calculated using the Kaplan-Meier method.
Time frame: At 1 year
Cumulative incidence of neutrophil and platelet engraftment
Will be calculated within the competing risks framework considering death without neutrophil or platelet recovery, respectively, as completing events
Time frame: Up to 1 year
Incidences of graft failure
Will be calculated within the competing risks framework considering death without engraftment before day 21 as a competing event.
Time frame: Up to 1 year
Incidence of grade II-IV and III-IV acute graft-versus-host disease (aGVHD)
Will be calculated within the competing risks framework considering relapse/ death without developing GVHD, death in the absence of relapse, and relapse as competing events, respectively.
Time frame: At day 100
Incidence of grade II-IV and III-IV aGVHD
Will be calculated within the competing risks framework considering relapse/ death without developing GVHD, death in the absence of relapse, and relapse as competing events, respectively.
Time frame: At day 180
Incidence of chronic graft-versus-host disease (cGVHD)
Will be calculated within the competing risks framework considering relapse/ death without developing GVHD, death in the absence of relapse, and relapse as competing events, respectively.
Time frame: At 1, 2 and 3 years
Organ distribution of GVHD
Will be calculated within the competing risks framework considering death without neutrophil or platelet recovery, respectively, as completing events
Time frame: Up to 1 year
Incidence of adverse events
Will be assessed using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).
Time frame: Up to 1 year
Time to immunosuppression cessation
Will be assessed using CTCAE v 5.0.
Time frame: Up to 1 year
Pattern of donor chimerism
Will be assessed using CTCAE v 5.0.
Time frame: Up to 1 year
Incidence of pre-engraftment syndrome (PES)
Will be assessed using CTCAE v 5.0.
Time frame: Up to 1 year
Incidence of transplant related mortality (TRM)
Time frame: At 100 days, 6 months, 1 and 2 years
Incidence of relapse
Time frame: At 1, and 2 years after CBT
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Oct 2031, 87 months after the start.
Of 42 phase 2 interventional studies under Leukemia, Biphenotypic, Acute, half reached primary completion within 102 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 153. This study's planned 87 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cyclophosphamide · Fludarabine phosphate
Leukemia, Biphenotypic, Acute →
Fred Hutchinson Cancer Center →